WO2002016355A3 - Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies - Google Patents

Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies Download PDF

Info

Publication number
WO2002016355A3
WO2002016355A3 PCT/US2001/022597 US0122597W WO0216355A3 WO 2002016355 A3 WO2002016355 A3 WO 2002016355A3 US 0122597 W US0122597 W US 0122597W WO 0216355 A3 WO0216355 A3 WO 0216355A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinuclidine
nicotinic
disease
treatment
substituted heteroaryl
Prior art date
Application number
PCT/US2001/022597
Other languages
English (en)
Other versions
WO2002016355A2 (fr
Inventor
Jason K Myers
Bruce N Rogers
Vincent E Groppi Jr
David W Piotrowski
Alice L Bodnar
Eric Jon Jacobsen
Jeffrey W Corbett
Original Assignee
Upjohn Co
Jason K Myers
Bruce N Rogers
Vincent E Groppi Jr
David W Piotrowski
Alice L Bodnar
Eric Jon Jacobsen
Jeffrey W Corbett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Jason K Myers, Bruce N Rogers, Vincent E Groppi Jr, David W Piotrowski, Alice L Bodnar, Eric Jon Jacobsen, Jeffrey W Corbett filed Critical Upjohn Co
Priority to EP01961664A priority Critical patent/EP1311505A2/fr
Priority to JP2002521456A priority patent/JP2004506734A/ja
Priority to AU2001282910A priority patent/AU2001282910A1/en
Publication of WO2002016355A2 publication Critical patent/WO2002016355A2/fr
Publication of WO2002016355A3 publication Critical patent/WO2002016355A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (I) pouvant se présenter sous la forme de sels ou de compositions pharmaceutiques, de mélanges racémiques ou de leurs énantiomères purs. Ces composés de formule (I) peuvent être utilisés dans des substances pharmaceutiques agissant sur l'activité des récepteurs α7.
PCT/US2001/022597 2000-08-21 2001-08-17 Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies WO2002016355A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01961664A EP1311505A2 (fr) 2000-08-21 2001-08-17 Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies
JP2002521456A JP2004506734A (ja) 2000-08-21 2001-08-17 疾患治療用のキヌクリド置換ヘテロアリール部分
AU2001282910A AU2001282910A1 (en) 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22665200P 2000-08-21 2000-08-21
US60/226,652 2000-08-21
US28483201P 2001-04-19 2001-04-19
US60/284,832 2001-04-19

Publications (2)

Publication Number Publication Date
WO2002016355A2 WO2002016355A2 (fr) 2002-02-28
WO2002016355A3 true WO2002016355A3 (fr) 2002-07-18

Family

ID=26920741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022597 WO2002016355A2 (fr) 2000-08-21 2001-08-17 Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies

Country Status (5)

Country Link
EP (1) EP1311505A2 (fr)
JP (1) JP2004506734A (fr)
AU (1) AU2001282910A1 (fr)
PE (1) PE20020505A1 (fr)
WO (1) WO2002016355A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003283648A1 (en) * 2002-12-06 2004-06-30 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
EP1587511A2 (fr) * 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Traitement de maladies l'aide d'agonistes totaux du récepteur nicotinique de l'acetycholine (achr) alpha-7
AU2004282201A1 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
SE0303076D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
SE0303075D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 4-substituted imidazoles
BRPI0417933A (pt) * 2003-12-22 2007-04-17 Astrazeneca Ab composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
KR20060125812A (ko) * 2003-12-22 2006-12-06 아스트라제네카 아베 니코틴성 아세틸콜린 수용체 리간드
JP2007538046A (ja) 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ 新規なアザビシクロアリール誘導体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
MX2010002258A (es) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Compuestos terapeuticos de isoxazol.
CA2701126A1 (fr) 2007-10-01 2009-04-09 Comentis, Inc. Derives de quinuclidine substitue en position 4, methodes de production et usages pharmaceutiques associes
WO2009098282A1 (fr) * 2008-02-06 2009-08-13 Novasaid Ab Dérivés de thiophène 2,5-disubstitués de faible poids moléculaire et leur utilisation en thérapie
RS52941B (en) 2008-02-13 2014-02-28 Targacept Inc. A COMBINATION OF ALFA 7 NICOTINE AGONISTS AND ANTIPSYCHOTICS
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EA024170B1 (ru) * 2011-02-23 2016-08-31 Люпин Лимитед ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ nAChR АЛЬФА7
WO2013005153A1 (fr) * 2011-07-05 2013-01-10 Lupin Limited Dérivés de biaryle en tant que modulateurs de nachr
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体
JPWO2014069554A1 (ja) * 2012-10-31 2016-09-08 東レ株式会社 キヌクリジンアミド誘導体及びその医薬用途
EP3166940A4 (fr) 2014-07-11 2018-04-25 Alpharmagen, LLC Composés de quinuclidine pour moduler l'activité du récepteur nicotinique alpha7 de l'acétylcholine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327335A1 (fr) * 1988-02-01 1989-08-09 Synthelabo Arylamido-et arylthioamido-azabicycloalcanes pour renforcer la mémoire ou corriger la déficience de la mémoire
EP0378111A1 (fr) * 1989-01-09 1990-07-18 ZAMBON GROUP S.p.A. Dérivés d'isoxazole doués d'activité antisérotonine, procédé pour leur préparation et compositions les contenant
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
WO1997030998A1 (fr) * 1996-02-23 1997-08-28 Astra Aktiebolag Esters azabicycliques d'acides carbamiques a usage therapeutique
WO1998054189A1 (fr) * 1997-05-30 1998-12-03 Neurosearch A/S Derives de spiro-quinuclidine, leur preparation et utilisation
WO2001036417A1 (fr) * 1999-11-18 2001-05-25 Astrazeneca Ab Nouvelle utilisation et nouveaux derives de n-azabicyclo-amide
WO2001060821A1 (fr) * 2000-02-18 2001-08-23 Astrazeneca Ab Nouveaux biarylcarboxamides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327335A1 (fr) * 1988-02-01 1989-08-09 Synthelabo Arylamido-et arylthioamido-azabicycloalcanes pour renforcer la mémoire ou corriger la déficience de la mémoire
EP0378111A1 (fr) * 1989-01-09 1990-07-18 ZAMBON GROUP S.p.A. Dérivés d'isoxazole doués d'activité antisérotonine, procédé pour leur préparation et compositions les contenant
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
WO1997030998A1 (fr) * 1996-02-23 1997-08-28 Astra Aktiebolag Esters azabicycliques d'acides carbamiques a usage therapeutique
WO1998054189A1 (fr) * 1997-05-30 1998-12-03 Neurosearch A/S Derives de spiro-quinuclidine, leur preparation et utilisation
WO2001036417A1 (fr) * 1999-11-18 2001-05-25 Astrazeneca Ab Nouvelle utilisation et nouveaux derives de n-azabicyclo-amide
WO2001060821A1 (fr) * 2000-02-18 2001-08-23 Astrazeneca Ab Nouveaux biarylcarboxamides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANNON A W ET AL: "BROAD-SPECTRUM, NON-OPIOID ANALGESIC ACTIVITY BY SELECTIVE MODULATION OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, no. 5347, 1998, pages 77 - 81, XP000906771, ISSN: 0036-8075 *
HOLLADAY ET AL: "Neuronal Nicotinic Acetylcholine Receptros as Targets for Drug Discovery", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 26, 19 December 1997 (1997-12-19), pages 4169 - 4194, XP002124847, ISSN: 0022-2623 *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 025 (C - 1017) 18 January 1993 (1993-01-18) *

Also Published As

Publication number Publication date
JP2004506734A (ja) 2004-03-04
AU2001282910A1 (en) 2002-03-04
EP1311505A2 (fr) 2003-05-21
PE20020505A1 (es) 2002-06-12
WO2002016355A2 (fr) 2002-02-28

Similar Documents

Publication Publication Date Title
WO2002016357A3 (fr) Composes aryle substitues par quinuclidine destines au traitement de maladies
WO2002015662A3 (fr) Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
WO2002016355A3 (fr) Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies
WO2002016358A3 (fr) Composes aryliques substitues par quinuclidine destines au traitement de maladies
WO2002017358A3 (fr) Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
WO2002016356A3 (fr) Composes aryle substitues par quinuclidine destines au traitement de maladies
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
WO2002100858A3 (fr) Composes aromatiques hetero-bicycliques substitues par quinuclidine dans le traitement de maladies
WO2003093250A3 (fr) Modulateurs allosteriques positifs de recepteur nicotinique de l'acetylcholine
WO2003070731A3 (fr) Composes azabicycliques servant a traiter des maladies
WO2004085433A3 (fr) Modulateurs allosteriques positifs du recepteur nicotinique de l'acetylcholine
WO2006011050A3 (fr) Derives de pyridine
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
CA2499330A1 (fr) Nouvelles quinazolinones spiro-condensees et utilisation associee en tant qu'inhibiteurs de phosphodiesterase
CA2410234A1 (fr) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl sous forme cristalline pure et procede de synthese
WO2005082892A3 (fr) Nouveaux composes de triazole en tant qu'agents antibacteriens et compositions pharmaceutiques en contenant
WO2005046589A3 (fr) Sels de composes de quinolinone acceptables d'un point de vue pharmaceutique et presentant des proprietes pharmaceutiques ameliorees
WO2005018557A3 (fr) Pyridinones substitues
NO20052802L (no) Pyrrolopyrimidinderivativer
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2003006670A3 (fr) Derives de l'acide 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinique en tant qu'inhibiteurs du facteur viia
PT992509E (pt) Novos derivados macrolidos
WO2005000815A3 (fr) Composes organiques
WO2002098850A3 (fr) Nouveaux composes et compositions utilises en tant qu'inhibiteurs de cathepsine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002521456

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001961664

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001961664

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001961664

Country of ref document: EP